This week we would like to highlight a recent review in Nephrology Dialysis Transplantation by Fred Jaisser and Jonatan Barrera-Chima entitled Mineralocorticoid receptor antagonism for non-diabetic kidney disease.
https://lnkd.in/eXVHKVxt
The beneficial effect of preventing renal structural damage, with a reduction in albuminuria while preserving renal function, is provided by mineralocorticoid receptor antagonists (MRAs) in models of non-diabetic chronic kidney disease (CKD).
It is recognised that activation of mineralocorticoid receptors in non-epithelial cells contributes to kidney damage by activating inflammatory and fibrotic pathways, increasing oxidative stress and modulating renal hemodynamics.
The protective effects of MRAs in animal models of CKD are not limited to the kidneys, and cardiovascular benefits are also observed (prevention of cardiac fibrosis, hypoperfusion and vascular calcification). But steroidal MRAs in patients with CKD are often proscribed because of the increased risk of hyperkalemia.
This review summarizes clinical trials testing the safety and efficacy of steroidal and non-steroidal MRAs in non-diabetic nephropathy.
A work of synthesis that deserves to be cited!
